3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
2
Active not recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
9
Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Recurrence
1
Rectal Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neutropenia
1
Neuroblastoma
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Cystadenocarcinoma, Serous
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Biliary Tract Neoplasms
1
Astrocytoma
1
Interventions
Carboplatin
49
Pemetrexed
38
Cisplatin
34
Radiotherapy
32
Docetaxel
31
Gemcitabine
25
Paclitaxel
24
Nivolumab
18
pembrolizumab
15
Etoposide
15
Radiosurgery
13
Erlotinib Hydrochloride
11
Bevacizumab
11
Magnetic Resonance Spectroscopy
10
Vinorelbine
9
Radiation
9
Cyclophosphamide
7
Gefitinib
6
Fluorodeoxyglucose F18
6
Celecoxib
6
durvalumab
5
atezolizumab
5
Oxaliplatin
5
Irinotecan
5
Immunoglobulin G
5
Drug Therapy
5
Disulfides
5
Dexamethasone
5
Chemotherapy, Adjuvant
5
vandetanib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lung Neoplasms
×
niraparib
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts